Screener
Krystal Biotech, Inc. KRYS Operating Income
Operating Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 7:06 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001711279-26-000043
| (in thousands, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Research and development | 15,331 | 14,256 |
| Selling, general and administrative | 41,014 | 32,647 |
| Total operating expenses | 62,668 | 51,931 |
| Income from operations | 53,689 | 36,252 |
| Other income | ||
| Interest and other income, net | 7,753 | 7,345 |
| Income before income taxes | 61,442 | 43,597 |
| Income tax expense | (5,510) | (7,864) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Krystal Biotech, Inc.'s operating income?
- Krystal Biotech, Inc. (KRYS) reported operating income of $53.69M in Q1 2026.
- How has Krystal Biotech, Inc.'s operating income changed year-over-year?
- Krystal Biotech, Inc.'s operating income increased by 48.1% year-over-year, from $36.25M to $53.69M.
- What is the long-term trend for Krystal Biotech, Inc.'s operating income?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s operating income has grown at a 24.0% compound annual growth rate (CAGR), from -$68.27M to $161.2M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Krystal Biotech, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude